Two cases of hypercholesterolaemic patients are presented in whom raised plasma creatine kinase was noted during treatment with statins. The plasma creatine kinase failed to fall following cessation of therapy. Further investigation revealed the aetiology of the raised plasma creatine kinase to be due to previously undiagnosed glycogen storage diseases (McArdle's and Pompe's diseases).
Case 1
An 18-year-old woman developed loin pain and proteinuria and was diagnosed with mesangial proliferative glomerulonephritis. Subsequently, she has remained normotensive with normal renal function (plasma creatinine 50 mmol/L). She had a relatively uneventful pregnancy and only required albumin infusions prior to a caesarean delivery. She was found to be hypercholesterolaemic (9.6 mmol/ L) and treatment with simvastatin 10 mg/day was commenced at the age of 31 years. Four weeks later her plasma creatine kinase (CK) was noted to be elevated, at 1311 IU/L (normal 5140 IU/L. The plasma CK remained persistently elevated at values up to 4000 IU/L despite stopping statin therapy for several months. All investigations for raised plasma CK, including plasma potassium, calcium, carnitine, thyroid function and CK electrophoresis, were normal.
A history was subsequently obtained of tiredness and poor exercise tolerance since she was 5 years old. This was associated with muscle sti¡ness after exercise but she characteristically developed a second-wind phenomenon of improved exercise tolerance with continuation of walking. She had bulky calves and brisk re£exes but no muscle tenderness or myotonia. McArdle's disease was diagnosed by an ischaemic exercise test which demonstrated no rise in lactate following ischaemia and reperfusion (basal plasma lactate 1.4 mmol/ L rising to a maximum 1.8 mmol/ L). A muscle biopsy failed to stain for phosphorylase.
Case 2
A male manual worker, presented aged 41 years with angina and was treated with coronary artery bypass grafts. He smoked 20 cigarettes a day, was found to be hypertensive and was treated with lisinopril. One year later, he was noted to be hyperlipidaemic, with a total cholesterol of 8.1 mmol/ L and triglycerides of 4.5 mmol/ L. Following a trial of dietary therapy, simvastatin 10 mg/ day was instituted with a fall in total cholesterol to 5.2 mmol/ L. However, after two months of therapy, plasma CK was found to be elevated, at 637 IU/L. Treatment was continued but he developed backache and cramps in the small muscles of his hands and the plasma CK was noted to be 747 IU/ L. Therapy was changed to beza¢brate, but the plasma CK remained elevated at 559 IU/L. Plasma CK remained elevated at 239-693 IU/L with and without any drug therapy. Other investigations for increased plasma CK were normal.
The mild elevation in plasma CK was considered to represent a mild myopathy due to heavy work, and statin therapy was continued. However, 4 years later, his brother, who had lifelong`weak muscles', was diagnosed with Pompe's disease. The index patient had no history of poor exercise tolerance, muscle pain or weakness, but the activity of acid a-glucosidase in his peripheral lymphocytes was markedly reduced, at 0.67 mmol/g/h (reference range 10-35), con¢rming a diagnosis of Pompe's disease.
Most recently, he has developed left ventricular and respiratory failures.
Discussion
These two cases demonstrate the di¤culties in interpreting elevations in CK, particularly when treatment with statins has been commenced without a baseline measurement. A mild myopathy with raised CK occurs in a small number of patients treated with both statins and ¢bric acid derivatives used for the treatment of hyperlipidaemia. This is relatively uncommon and therefore many practitioners do not routinely monitor CK during therapy. Elevations in CK are usually considered to be signi¢cant at concentrations of greater than three or four times the upper reference value. This is because plasma CK is very easily elevated by minor degrees of muscle injury such as occurs after heavy manual work, vigorous sport or intramuscular injections. Metabolic causes of elevated CK include hypothyroidism and de¢ciencies of magnesium, calcium, potassium and carnitine (the latter is often present in renal failure); false elevations occur with macro-forms of CK due to complexes of CK with Igs. There are ethnic variations in CK 1 and some individuals have idiopathic elevations of CK. 2 Case 1 gives a fairly characteristic history for McArdle's disease (myophosphorylase de¢ciency). These patients typically develop muscle pain on exercise with a`second-wind' phenomenon. In childhood, the main symptom is of fatigability, and only in adulthood (20-40 years) do cramps and myoglobinuria develop. Case 2, in contrast, gives an unusual story for Pompe's disease (glycogen storage disease type II). This is a relatively common autosomally recessive condition with several modes of presentation. In infancy, the presentation is with generalized muscle weakness and cardiac enlargement, and in childhood or adult life with progressive muscle weakness. Asymptomatic cases as described above must be considered unusual. Pompe's disease di¡ers from the other glycogen storage disorders that are involved in intermediary metabolism as it is due to the absence of a-glucosidase which cleaves glycogen only within lysosomes.
Inherited myopathies are rare causes of elevation in CK and, moreover, it is extremely unusual for an elevated CK to be a presenting diagnostic feature. 3 These two cases highlight the need to consider all causes of myopathy even when a potentially myotoxic therapy is being taken.
